Relistor FDA Approval History
FDA Approved: Yes (First approved April 25, 2008)
Brand name: Relistor
Generic name: methylnaltrexone bromide
Dosage form: Tablets and Subcutaneous Injection
Company: Salix Pharmaceuticals, Inc.
Treatment for: Constipation
Relistor (methylnaltrexone) is a peripherally acting mu-opioid receptor antagonist indicated to treat opioid-induced constipation.
Development Timeline for Relistor
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.